ES2571991T3 - Procedures for treating and / or reversing diseases and / or neurodegenerative disorders - Google Patents
Procedures for treating and / or reversing diseases and / or neurodegenerative disordersInfo
- Publication number
- ES2571991T3 ES2571991T3 ES11746068T ES11746068T ES2571991T3 ES 2571991 T3 ES2571991 T3 ES 2571991T3 ES 11746068 T ES11746068 T ES 11746068T ES 11746068 T ES11746068 T ES 11746068T ES 2571991 T3 ES2571991 T3 ES 2571991T3
- Authority
- ES
- Spain
- Prior art keywords
- neural stem
- procedures
- treating
- neurodegenerative disorders
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Una cantidad terapéuticamente eficaz de una población expandida de células madre neurales a partir de al menos una célula madre neural obtenida a partir del tejido de la médula espinal de un ser humano, para su uso en el tratamiento de una enfermedad o un trastorno asociado a la pérdida de células neuronales en cerebro, en la que la población de células madre neurales es para la administración a al menos un área del cerebro de un sujeto; y en la que la población de células madre neurales es para la administración a, cerca de o alrededor de, el área o las áreas, el cerebro del sujeto afectadas por la pérdida de células neuronales.A therapeutically effective amount of an expanded population of neural stem cells from at least one neural stem cell obtained from the spinal cord tissue of a human being, for use in the treatment of a disease or disorder associated with the loss of neuronal cells in the brain, in which the population of neural stem cells is for administration to at least one area of the brain of a subject; and in which the population of neural stem cells is for administration to, near or around, the area or areas, the subject's brain affected by the loss of neuronal cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36840910P | 2010-07-28 | 2010-07-28 | |
PCT/US2011/045732 WO2012016049A1 (en) | 2010-07-28 | 2011-07-28 | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2571991T3 true ES2571991T3 (en) | 2016-05-27 |
Family
ID=44630526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11746068T Active ES2571991T3 (en) | 2010-07-28 | 2011-07-28 | Procedures for treating and / or reversing diseases and / or neurodegenerative disorders |
Country Status (16)
Country | Link |
---|---|
US (1) | US9540611B2 (en) |
EP (1) | EP2598154B1 (en) |
JP (2) | JP6077996B2 (en) |
KR (1) | KR101765980B1 (en) |
CN (1) | CN103237553A (en) |
AU (1) | AU2011282642B2 (en) |
CA (1) | CA2806904C (en) |
ES (1) | ES2571991T3 (en) |
IL (1) | IL224416A (en) |
MX (1) | MX341316B (en) |
MY (1) | MY168084A (en) |
NZ (2) | NZ607195A (en) |
RU (1) | RU2013108868A (en) |
SG (1) | SG187226A1 (en) |
WO (1) | WO2012016049A1 (en) |
ZA (1) | ZA201300954B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006055685A2 (en) * | 2004-11-17 | 2006-05-26 | Neuralstem, Inc. | Transplantation of human neural cells for treatment of neurodegenerative conditions |
US9789073B2 (en) | 2013-03-14 | 2017-10-17 | Pathak Holdings, Llc | Compositions, methods and devices for local drug delivery |
WO2014160387A2 (en) * | 2013-03-14 | 2014-10-02 | Pathak Holdings, Llc | Compositions, methods and devices for local drug delivery |
US9072678B2 (en) | 2013-03-14 | 2015-07-07 | Pathak Holdings Llc | Methods for local drug delivery by microinjection |
US10624865B2 (en) | 2013-03-14 | 2020-04-21 | Pathak Holdings Llc | Methods, compositions, and devices for drug/live cell microarrays |
WO2015006474A1 (en) * | 2013-07-09 | 2015-01-15 | Neuralstem, Inc. | Methods of treating a subject with a cognitive dysfunction using spinal cord-derived neural stem cells |
AU2015279552B2 (en) | 2014-06-27 | 2021-01-21 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
WO2017031092A1 (en) * | 2015-08-15 | 2017-02-23 | Asterias Biotherapeutics, Inc. | Stem cell-derived oligodendrocyte progenitor cells for the treatment of white matter stroke |
CN106619722A (en) * | 2016-12-05 | 2017-05-10 | 上海安集协康生物技术股份有限公司 | Neural stem cell injection for treating brain damage disease |
CN115089613A (en) * | 2022-07-25 | 2022-09-23 | 朗姿赛尔生物科技(广州)有限公司 | Application of neural stem cell transplantation in neurodegenerative diseases |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0233838A3 (en) | 1986-02-04 | 1990-01-31 | Incyte Pharmaceuticals, Inc. | Neurite-promoting factor and process for the manufacture thereof |
US4753635A (en) | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
NZ226750A (en) | 1987-10-29 | 1990-09-26 | Amrad Corp Ltd | Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene |
WO1990001541A1 (en) | 1988-08-04 | 1990-02-22 | Amrad Corporation Limited | In vitro propagation of embryonic stem cells |
US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US4980174A (en) | 1988-12-23 | 1990-12-25 | Jacqueline Sagen | Method for alleviating depression |
WO1991002003A1 (en) | 1989-08-04 | 1991-02-21 | Board Of Regents, The University Of Texas System | Methods and compositions; purified preparation of neural progenitor regulatory factor |
US5411883A (en) | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
WO1991009936A1 (en) | 1989-12-26 | 1991-07-11 | Hana Biologics, Inc. | Proliferated neuron progenitor cell product and process |
US5196315A (en) | 1990-05-01 | 1993-03-23 | The Johns Hopkins University | Human neuronal cell line |
US5612211A (en) | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
ATE240389T1 (en) | 1991-07-08 | 2003-05-15 | Neurospheres Holdings Ltd | NEURAL PRONECTOR CELLS RESPONDING TO GROWTH FACTORS THAT CAN BE PROPAGATED IN VITRO. |
US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
US6071889A (en) | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US6294346B1 (en) | 1991-07-08 | 2001-09-25 | Neurospheres Holdings, Ltd. | Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents |
US7361505B1 (en) | 1991-07-08 | 2008-04-22 | Neurospheres Holdings Ltd. | Multipotent neural stem cell compositions |
US5981165A (en) | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US6399369B1 (en) | 1991-07-08 | 2002-06-04 | Neurospheres Holdings Ltd. | Multipotent neural stem cell cDNA libraries |
US5175103A (en) | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
ES2133333T3 (en) | 1991-11-22 | 1999-09-16 | Genentech Inc | TGF-BETA TO IMPROVE THE RECOVERY OF NEURONS. |
JPH08500245A (en) | 1992-07-27 | 1996-01-16 | カリフォルニア インスティテュート オブ テクノロジー | Mammalian pluripotent neural stem cells |
US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
US5849553A (en) | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
US5672499A (en) | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
AU4995193A (en) | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
AU4950393A (en) | 1992-08-19 | 1994-03-15 | Richard Kroczek | Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family |
EP1298202B1 (en) | 1992-10-28 | 2010-10-06 | NeuroSpheres Holdings Ltd. | Biological factors and neural stem cells |
ATE230795T1 (en) | 1993-11-09 | 2003-01-15 | Neurospheres Holdings Ltd | IN SITU MODIFICATION AND MANIPULATION OF CENTRAL NERVOUS SYSTEM STEM CELLS |
DK0783693T3 (en) | 1994-09-23 | 2002-01-14 | Neurospheres Holdings Ltd | In vitro models for CNS function and dysfunction |
AU716811B2 (en) | 1994-11-14 | 2000-03-09 | Neurospheres Holdings Ltd | Regulation of neural stem cell proliferation |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5753505A (en) | 1995-07-06 | 1998-05-19 | Emory University | Neuronal progenitor cells and uses thereof |
US5770414A (en) | 1996-02-20 | 1998-06-23 | The Regents Of The University Of California | Regulatable retrovirus system for genetic modification of cells |
US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
US5753506A (en) | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
WO1998048001A1 (en) | 1997-04-24 | 1998-10-29 | California Institute Of Technology | Methods for differentiating neural stem cells |
AU755657B2 (en) | 1997-07-04 | 2002-12-19 | University Of Utah Research Foundation | Lineage-restricted neuronal precursors |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US5932473A (en) | 1997-09-30 | 1999-08-03 | Becton Dickinson And Company | Preparation of a cell culture substrate coated with poly-D-lysine |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
JP4709382B2 (en) | 1998-09-22 | 2011-06-22 | ニューラルステム バイオファーマシューティカルズ、リミテッド | Stable neural stem cell line |
US6284539B1 (en) | 1998-10-09 | 2001-09-04 | Neuralstem Biopharmaceuticals, Ltd. | Method for generating dopaminergic cells derived from neural precursors |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
HN2001000224A (en) | 2000-10-19 | 2002-06-13 | Pfizer | IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS. |
ES2274973T3 (en) | 2001-04-23 | 2007-06-01 | The Trustees Of The University Of Pennsylvania | INHIBITORS OF THE AGGREGATION OF AMYLOID PLATES AND AGENTS FOR OBTAINING DIAGNOSTIC IMAGES. |
AU2002350127A1 (en) | 2001-06-22 | 2003-01-08 | The University Of Texas System | Method of producing region-specific neurons from human neuronal stem cells |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
WO2006055685A2 (en) * | 2004-11-17 | 2006-05-26 | Neuralstem, Inc. | Transplantation of human neural cells for treatment of neurodegenerative conditions |
US20120107284A1 (en) * | 2006-06-30 | 2012-05-03 | Elena Kozlova | Stem cells for transplantation and methods for production thereof |
-
2011
- 2011-07-28 MX MX2013001124A patent/MX341316B/en active IP Right Grant
- 2011-07-28 AU AU2011282642A patent/AU2011282642B2/en active Active
- 2011-07-28 EP EP11746068.3A patent/EP2598154B1/en active Active
- 2011-07-28 CN CN2011800463741A patent/CN103237553A/en active Pending
- 2011-07-28 MY MYPI2013000300A patent/MY168084A/en unknown
- 2011-07-28 NZ NZ607195A patent/NZ607195A/en not_active IP Right Cessation
- 2011-07-28 ES ES11746068T patent/ES2571991T3/en active Active
- 2011-07-28 SG SG2013006614A patent/SG187226A1/en unknown
- 2011-07-28 JP JP2013521977A patent/JP6077996B2/en active Active
- 2011-07-28 NZ NZ623207A patent/NZ623207A/en not_active IP Right Cessation
- 2011-07-28 CA CA2806904A patent/CA2806904C/en active Active
- 2011-07-28 US US13/192,972 patent/US9540611B2/en active Active
- 2011-07-28 KR KR1020137004632A patent/KR101765980B1/en active IP Right Grant
- 2011-07-28 WO PCT/US2011/045732 patent/WO2012016049A1/en active Application Filing
- 2011-07-28 RU RU2013108868/15A patent/RU2013108868A/en unknown
-
2013
- 2013-01-27 IL IL224416A patent/IL224416A/en active IP Right Grant
- 2013-02-05 ZA ZA2013/00954A patent/ZA201300954B/en unknown
-
2015
- 2015-08-27 JP JP2015167720A patent/JP2015214589A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MX2013001124A (en) | 2013-08-01 |
JP6077996B2 (en) | 2017-02-08 |
EP2598154A1 (en) | 2013-06-05 |
AU2011282642A1 (en) | 2013-03-07 |
US20120177612A1 (en) | 2012-07-12 |
IL224416A (en) | 2017-06-29 |
AU2011282642B2 (en) | 2015-06-11 |
RU2013108868A (en) | 2014-09-10 |
MY168084A (en) | 2018-10-11 |
JP2015214589A (en) | 2015-12-03 |
MX341316B (en) | 2016-08-15 |
WO2012016049A1 (en) | 2012-02-02 |
EP2598154B1 (en) | 2016-03-23 |
CA2806904C (en) | 2018-11-27 |
ZA201300954B (en) | 2014-04-30 |
KR20140048064A (en) | 2014-04-23 |
US9540611B2 (en) | 2017-01-10 |
NZ623207A (en) | 2014-12-24 |
KR101765980B1 (en) | 2017-08-07 |
SG187226A1 (en) | 2013-03-28 |
CA2806904A1 (en) | 2012-02-02 |
CN103237553A (en) | 2013-08-07 |
NZ607195A (en) | 2014-08-29 |
JP2013532690A (en) | 2013-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2571991T3 (en) | Procedures for treating and / or reversing diseases and / or neurodegenerative disorders | |
EP4272757A3 (en) | Modified nk-92 cells for treating cancer | |
WO2015008154A3 (en) | Self-administrable method, system, and apparatus for non-invasive neurostimulation therapy of the brain | |
EP3818991A3 (en) | Compositions and methods for treating diseases | |
UY33481A (en) | COMPOSITE FOR THE TREATMENT OF DISORDERS AND DISEASES OF THE OCULAR BACK SEGMENT | |
BR112013018919A2 (en) | empty nanoparticle compositions and their use to treat dermatological problems | |
MX2015002289A (en) | Human antibodies to gfrî±3 and methods of use thereof. | |
CY1120642T1 (en) | PHARMACEUTICAL COMPOSITION OF IBUPROFEMEN AND TRAMADOL FOR OPHTHALMOLOGICAL USE | |
MX356343B (en) | Compounds which inhibit neuronal exocytosis (ii). | |
EA201891507A1 (en) | ACID ALPHA-GLUCOSIDASE OF STRENGTHENING ACTION FOR THE TREATMENT OF POMPE DISEASE | |
WO2010018996A3 (en) | Human neural stem cell, and pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same | |
RU2016139716A (en) | Synthesis of elastic fiber in vivo | |
EA201891007A1 (en) | AIMING FOR FORMILPEPTID RECEPTOR 2 / LIPOXIN A RECEPTOR (FPR2 / ALX) FOR TREATING HEART DISEASES | |
ATE452968T1 (en) | RETINA-SPECIFIC CELLS DIFFERENTIATED IN VITRO FROM BONE MARROW STEM CELLS, THEIR PRODUCTION AND USE | |
UY33153A (en) | TYPICAL OPTIMAL FORMULATION OF PEPTIDES | |
EP3590338A3 (en) | Medical treatments based on anamorelin | |
MX2015016062A (en) | Human monocyte sub-population for treatment of eye diseases and disorders. | |
UA109359C2 (en) | TREATMENT OF SKIN DISEASES AND STATES | |
AR110947A1 (en) | TREATMENT OF RETINA DEGENERATION THROUGH THE USE OF PROGENITING CELLS | |
Smyk et al. | The use of body-oriented psychotherapy for psychosomatic pathology | |
EP3903789A4 (en) | Therapeutic drug for disease accompanied by disorders in retinal system cells or retinal tissue | |
WO2014003850A3 (en) | Methods for treatment of ocular diseases | |
WO2012083128A3 (en) | Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death | |
EA201600229A1 (en) | BIS (5-AMINO-1,4-DIOXO-1,2,3,4-TETRAHYDRO-PHTHALAZIN-2-AIHs) ZINC, METHOD FOR ITS OBTAINING, PHARMACEUTICAL COMPOSITION ON ITS BASIS, MEDICAL MEANS ON ITS BASIS, SPECIAL SYSTEMS AND HEATS ARE BASED, ITEM-BASED, MEDICAL MEANS ON ITS BASIS, SPECIAL TESTS TREATMENT OF GASTRITIS | |
CN202554237U (en) | Health-care eye patch |